Abstract: The present invention refers to new epitopes recognized by CD4+ T-lymphocytes. In addition, the present invention refers to the uses of such epitopes and their combinations, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to a composition comprising said epitopes and the uses of said composition, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to anti-HIV-1 prophylactic vaccines and therapeutic vaccines. Furthermore, the present invention refers to a method for the identification of epitopes and methods for treating or preventing an infection caused by the HIV-1 virus.

Abstract: VACCIN AGAINST GROUP A BETA HEMOLYTIC STREPTOCOCCUS AND RESPECTIVE PROCESS FOR OBTAINING THEREOF, which predicts the production of recombinant protein cloned from the gene emm5, which contains a sequence of oligonucleotides corresponding to 52 and/or 87 amino acid residues capable of protection, isolated after the sequential molecular identification of the epitopes from the M protein carboxy-terminal region, differing in 01 amino acid residue, identified by antibodies and T lymphocytes of health human beings and of patients carriers of rheumatic fever, capable of generating a protective response by antibodies depending on the T lymphocytes; prevention of the development of the autoimmune disease by the selected epitope was evaluated in vitro with T lymphocytes from the cardiac tissue of patients with lesions arising out of rheumatic fever.

Abstract: The present invention refers to new epitopes recognized by CD4+ T-lymphocytes. In addition, the present invention refers to the uses of such epitopes and their combinations, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to a composition comprising said epitopes and the uses of said composition, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to anti-HIV-1 prophylactic vaccines and therapeutic vaccines. Furthermore, the present invention refers to a method for the identification of epitopes and methods for treating or preventing an infection caused by the HIV-1 virus.

Abstract: “PROCESS FOR TREATMENT OF BIOLOGICAL TISSUES”, where an additional step has been added to the conventional biological tissue treatment process—lyophilization—where the material is frozen and then the frozen liquid portion is removed through vacuum sublimation; where a complementary step of tissue reconstitution is obtained through re-hydration of the material with saline solution, thereby evaporating almost all aldehyde residual material resulting in less calcification and increased valve durability after implantation; the application of lyophilization to non-treated, in natura (fresh) bovine pericardium for storage purposes; the application of lyophilization to devices made from treated bovine pericardium; and the application of lyophilization to valve prostheses manufactured from chemically pre-treated pig heart valves.